Please assess the completion status of the following clinical trial:

Trial Title: Angiotensin Receptors and Age Related Mitochondrial Decline in HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* able to provide informed consent~* able to attend an extended (\~4 hour) Clinical Research Visit~* documented HIV seropositivity~* on a stable anti-retroviral therapy (ART) regimen for at least 12 months~* HIV plasma viral load \< 50 copies/ml for at least 6 months~* Systolic blood pressure \>110~Exclusion Criteria:~* creatinine \> 1.5 ULN (or creatinine clearance \< 60 ml/min)~* anti-hypertensive therapy with ACE-I or AT1R-blockers~* inability to perform functional measures (e.g. non-ambulatory without assistance, requires a prosthesis)~* recent (within 30 days) acute illness requiring medical therapy or hospitalization~* immunosuppressive agents (e.g. \> 20 mg/d x 2 or more weeks of prednisone or equivalent, chemotherapy) in the last 6 months~* cancer requiring treatment w/in 3 yrs (except for non-melanoma skin cancer)~* blood thinning medications such as Coumadin or Plavix or a bleeding disorder such as hemophilia that could cause complications during muscle biopsies~* pregnancy (will provide urine test for females of child bearing potential)~* regular use of non-steroidal anti-inflammatory drugs or other immune modulating agents.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo control (Type: PLACEBO_COMPARATOR): 20 HIV-infected participants will be randomized into a blinded arm where they will receive 24 weeks of placebo therapy. During this time, they will undergo the same study procedures as the intervention arm.
- Valsartan (Type: EXPERIMENTAL): 20 HIV-infected participants will be randomized into a blinded arm where they receive 24 weeks of valsartan therapy. For those subjects randomized to the valsartan group, they will receive valsartan 40 mg by mouth daily for 2 weeks, then increase to 80 mg by mouth daily for the remaining 22 weeks. During this time, they will undergo the same study procedures as the placebo arm.

Based on this trial design, predict the completion outcome and termination type (if applicable).